

Celltrion Healthcare

3Q22 Earnings Presentation



Contents

Section 01. 3Q22 Business Results

Section 02. Key Business Performance

Appendix






- Revenue : Steady growth continued in Remsima[®] SC and all other products in Europe & the growth market led sound earnings, partially offset sales reduction in North America
- ► OP : Achieved solid operating profit mainly driven by stable prescription & COGS improvement of the high-margin products such as Inflectra[®] and Remsima[®] SC
- **NP** : Jumped by 238.9% YoY and 251.9% QoQ respectively as a result of the increase in non-operating profit due to weak Won

(KRW bn)	′21.3 Q	′22.2 Q	′22.3 Q	%ΥοΥ	%QoQ	
Revenue	409.1	519.0	496.4	21.3%	-4.4%	
Gross Profit	74.7	140.9	153.1	105.0%	8.7%	
(%)	18.3%	27.1%	30.8%	12.5%p	3.7%p	
SG&A	52.7	66.8	80.6	52.9%	20.7%	
(%)	12.9%	12.9%	16.2%	3.3%p	3.3%p	
Personnel expenses	12.1	13.7	14.1	16.5%	2.9% -62.5%	
Research expenses	5.5	0.8	0.3	-94.5%		
Advertising expenses	3.0	6.6	7.7	156.7%	16.7%	
Commissions	14.9	24.3	33.1	122.1%	36.2%	
Operating Profit	22.0	74.1	72.5	229.5%	-2.2%	
(%)	5.4%	14.3%	14.6%	9.2%p	0.3%p	
EBIT	52.5	95.2	185.2	252.8%	94.5%	
Net Profit	40.6	39.1	137.6	238.9%	251.9%	

Sales Breakdown



Investor Relations 2022 5

Balance Sheet

'21	'22.3Q	Change	
3,914.7	4,559.0	644.3	
254.9	285.0	30.1	
270.5	213.1	-57.4	
584.1	858.5	274.4	
2,065.7	2,424.0	358.3	
1,808.9	2,364.1	555.2	
2,105.8	2,194.9	89.1	
85.9%	107.7%	21.8%p	
	3,914.7 254.9 270.5 584.1 2,065.7 1,808.9 2,105.8	3,914.7 4,559.0 254.9 285.0 270.5 213.1 584.1 858.5 2,065.7 2,424.0 1,808.9 2,364.1 2,105.8 2,194.9	

Cash Flow


(KRW bn)	'21	′22.3Q	
Cash at beginning of year	231.5	254.9	
Operating	-160.2	130.1	
Operating profit	199.4	191.6	
Working capital	-340.2	-42.0	
Others	-19.4	-19.5	
Investing	-4.2	65.1	
Short term financial assets	28.0	72.8	
Others	-32.2	-7.7	
Financing	187.8	-165.1	
Borrowing and redemption	199.9	-34.6	
Share buyback	-11.6	-91.0	
Cash Dividend	-	-39.9	
Share issue	3.0	3.5	
Others	-3.5	-3.1	
Cash at the end of year	254.9	285.0	



Section 02


Key Business Performance

- As the most prescribed Infliximab drug, Remsima[®] has steady market share uptake after launching Remsima[®] SC in Europe & continuously expanding prescription in Japan & LATAM
- In the US, the market share uptake continued by accelerating prescription after additional listings at major
 US payers



M/S of Remsima[®] in Europe and Japan


Source : IQVIA



Note: The market share is based on volume Source : Symphony Health


M/S of Inflectra® in the US

- Remsima[®] SC prescription has been expanding since its launch in 2020 and driving the growth of Infliximab market in Europe
- ✓ Switching from Inflectra[®] to Remsima[®] led to the increase of prescription of Remsima[®] SC



M/S Trend of CTHC's Infliximab products in Europe

M/S of Infliximab products in Europe (as of 2Q22)




Note: The market share is based on volume of EU regions Remsima® SC launched Source : IQVIA


Remsima® SC

- Real-world Remsima[®] SC switching data has been presented at UEGW 2022
- ✓ Infliximab levels significantly increased post switch to Remsima[®] SC at 3m & remained high to 12m
- ✓ According to the survey, 77% of patients preferred using Remsima[®] SC over Infliximab IV

Infliximab PK levels of Remsima[®] SC switching patients


Patient satisfaction survey after switching to Remsima[®] SC






Source : Philip J Smith et al Efficacy and Safety of Elective Switching From Intravenous to Subcutaneous Infliximab (Ct-P13): A Multi-Centre Cohort Study, Journal of Crohn's and Colitis, 2022;, jjac053, https://doi.org/10.1093/ecco-jcc/jjac053

- In Europe, the market share has decreased during the transition to go direct in 1H22, expected to be recovered gradually with the start of direct sales in 2H22
- Despite pricing pressure amid intensified competition, maintaining stable market share in the US




M/S of Truxima[®] in Europe



M/S of Truxima[®] in the US

Source : Symphony Health



Note: The market share is based on volume

Source : IQVIA

17.4Q

31%

18.2Q


Herzuma®

- ✓ Herzuma[®], a leading trastuzumab biosimilar in Europe, started to go direct in 2H22
- Surpassed the market share of Herceptin[®] in Japan & Increasing demands in LATAM boosted the sales growth


M/S of Herzuma[®] in Europe

Note: The market share is based on volume

Source : IQVIA



M/S of Herzuma[®] in Japan




Note: The market share is based on volume Source : IQVIA

Investor Relations 2022 12

Yuflyma®

- ✓ Yuflyma[®], a biosimilar with Humira[®]'s most similar specification, will be launched in the US in Jul.2023
- Initiated a global Phase 3 clinical trial to demonstrate the interchangeability of Yuflyma[®] with Humira[®]



Global market size of Adalimumab

Specifications by product

Product Name	High concentration	Interchangeability
Humira®	Ο	-
Yuflyma®	Ο	Δ
А	Х	Δ
В	Ο	Δ
С	Ο	Δ
D	Х	Ο


Note: \triangle indicates clinical trial to support interchangeability ongoing

Note: The market size is as of 2021 Source : IQVIA



Appendix

Launching Timeline by Product



Note: 1) The logo of Inflectra[™] is owned by Pfizer

2) Launching plan could be subjective to the approval

Pipeline

Product Name	Reference Drug	Manufacturer	Global Market size (^{\$bn)}	US	EU			
Remsima [®] SC	-	Celltrion	52.9	In phase 3 clinical trial	Received EMA approval (Jul.2020, Pediatric usage non-included)			
Yuflyma®	Humira®	AbbVie	34.6	Application submitted (Nov.2020)	Received EMA approval (Feb.2021)			
Turryina	(Adalimumab)		54.0	In phase 3 clinical trial to support interchangeability				
Vegzelma®	Avastin® (Bevacizumab)	Roche	6.1	Received FDA approval (Sep.2022)	Received EMA approval (Aug.2022)			
СТ-Р43	Stelara® (Ustekinumab)	Johnson & Johnson	14.1	In phase 3 clinical trial				
СТ-РЗ9	Xolair® (Omalizumab)	Genentech	3.7	In phase 3 clinical trial				
CT-P42	Eylea® (Aflibercept)	Bayer & Regeneron	4.8	In phase 3 clinical trial				
CT-P41	Prolia® (Denosumab)	Amgen	5.8	In phase 3 clinical trial				
CT-P47	Actemra [®] (Tocilizumab)	Roche	3.6	In phase 3 clinical trial				

Note: Global market size is as of 2021 Source : IQVIA

Summary Income Statement

(KRW bn)	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22	'19	'20	'21
Revenue	356.9	420.3	463.4	387.0	356.3	433.3	409.1	605.8	415.7	519.0	496.4	1,100.9	1,627.6	1,804.5
Cost of Sales	262.4	292.0	289.4	242.0	274.0	306.1	334.4	459.5	311.4	378.1	343.3	891.6	1,085.8	1,374.0
Gross Profit	94.5	128.3	174.0	145.0	82.3	127.1	74.7	146.4	104.3	140.9	153.1	209.3	541.8	430.5
SG&A	38.7	41.4	46.3	53.3	50.8	50.9	52.7	76.7	59.2	66.8	80.6	126.5	179.7	231.1
Operating Income (Loss)	55.8	86.8	127.7	91.8	31.5	76.2	22.0	69.7	45.0	74.1	72.5	82.8	362.1	199.4
Non-operating Income	42.4	(18.1)	(7.0)	(64.5)	3.6	11.8	30.5	(45.9)	16.5	21.2	112.9	(6.7)	(47.2)	0.0
Financial Income	22.8	3.6	3.1	9.2	5.5	4.6	2.2	0.8	4.3	3.4	22.8	20.0	38.7	13.1
Financial Expenses	7.4	16.9	8.2	1.4	12.5	3.5	18.5	(2.8)	5.0	13.9	17.2	29.5	33.9	31.7
Other Income	32.5	11.7	7.4	(13.2)	27.0	15.6	51.8	(22.6)	30.9	38.8	114.0	20.8	38.4	71.8
Other Expenses	5.5	16.5	9.3	59.1	16.4	4.9	5.0	26.9	13.7	7.1	6.7	18.0	90.4	53.2
Profit before Taxes	98.2	68.7	120.6	27.2	35.0	87.8	52.5	23.0	61.3	95.2	185.2	75.4	314.7	198.3
Tax Expense (Benefit)	22.0	22.2	34.5	(4.4)	3.5	24.1	11.9	(85.2)	17.7	56.1	47.5	10.4	74.3	(45.7)
Net Profit	76.2	46.4	86.1	31.7	31.5	63.7	40.6	16.8	43.6	39.1	137.6	65.0	240.4	152.6



Thank You